INOGENIX
INOGENIX provides AI-driven molecular diagnostic products and services that enable earlier detection and personalized treatment decisions. The company develops diagnostic assays and devices using AI, liquid biopsy, genetic testing and CRISPR-Cas12a technology, and sells these as a mix of SaaS, subscription, and laboratory services to healthcare providers and diagnostic labs. Its offerings include atopy prediction genetic tests, colorectal cancer screening, COVID-19 diagnostics, and infectious disease monitoring. INOGENIX operates R&D and testing facilities in South Korea with a liaison office in Canada and targets clinical and institutional customers seeking prevention- and early-diagnosis solutions in molecular diagnostics.
INOGENIX
INOGENIX provides AI-driven molecular diagnostic products and services that enable earlier detection and personalized treatment decisions. The company develops diagnostic assays and devices using AI, liquid biopsy, genetic testing and CRISPR-Cas12a technology, and sells these as a mix of SaaS, subscription, and laboratory services to healthcare providers and diagnostic labs. Its offerings include atopy prediction genetic tests, colorectal cancer screening, COVID-19 diagnostics, and infectious disease monitoring. INOGENIX operates R&D and testing facilities in South Korea with a liaison office in Canada and targets clinical and institutional customers seeking prevention- and early-diagnosis solutions in molecular diagnostics.